UroToday.com - Androgen-deprivation therapy (ADT) decreases PCSM, but may be associated with greater risk of occurrence coronary artery complaint (CAD), myocardial infarction and diabetes. Observations from RTOG 85-31, a generous trial of radiotherapy with or without ADT was used for this analysis. 945 men were randomized, and 50% of men were over age 70. Median duration of ADT was 4.2 years, and 64% of the radiotherapy patients last analysis received ADT at a mean moment interval of 3 years.
A total of 574 deaths occurred, and 117 were CV common. No ADT interrelated raise in CV mortality was found. In multivariate analysis of CV mortality with and without censoring at time of salvage ADT, ADT was not associated with increased CV mortality in men with locally advanced CaP. This is consistent with 5 other reports that ADT and radiotherapy is not associated with increased CV mortality. A CaPSURE report in 2007 reported a 4% increased risk of CV death with ADT in patients who had rudimentary prostatectomy. An ADT increasing in non-cancer CV mortality may under any circumstances occur, inclusive of other mechanisms, such as additive with diabetes.
Presented by J. A. Efstathiou at the American Society of Clinical Oncology (ASCO) - 2008 Genitourinary Cancers Symposium - A Multidisciplinary Solicit - February 14-16, 2008 San Francisco, California, USA
Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS Professor & Chairman Turn on of Urology University of California, Davis, High school of Physic Sacramento, CA
UroToday - the only urology website with original content written by wide-ranging urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to:
www.urotoday.com
—————————-
Copyright © 2007 - UroToday
Reproduced for Medical News Today with permission of UroToday.
—————————-